This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More
Joshua Brown

ARCHIVES

Brokerage Partners

Curated by Joshua Brown, The Reformed Broker

Side Street

View From the Blogs

Market Folly

Visit My Web Site

Jay is the author of www.MarketFolly.com, a site that tracks top hedge funds and provides daily updates on what they're buying, selling and why. MarketFolly covers SEC filings, hedge fund letters, buyside investment conferences and more.

Seth Klarman's Favorite Biotech Stock

Posted on 02/11/13 - 12:17 PM EST

Seth Klarman's firm Baupost Group recently filed an amended 13G with the SEC regarding its position in Idenix Pharmaceuticals (IDIX). Per the filing, Baupost Group now owns 18.48% of the company with 24,740,200 shares.

This marks around a 106% increase in the number of shares they own since the end of the third quarter. The filing was made due to portfolio activity on January 31st.

Per Google Finance, Idenix Pharmaceuticals "is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and Europe. The Company's research and development focus is on the treatment of hepatitis C virus (HCV)."

You can see more of Baupost Group's portfolio activity here.

THE BLOG: http://www.marketfolly.com/2013/02/seth-klarmans-baupost-group-increases.html

The content provided within this blog is property of market folly and any views or opinions expressed herein are those solely of market folly and do not represent that of any firm or institution. This website is for educational and/or entertainment purposes only. Use this information at your own risk. Market folly is not an investment advisor of any kind, so do not consider anything on this page to be legal, tax, or investment advice. Market folly is not responsible for any 3rd party links or content.

Top Rated Stocks Top Rated Funds Top Rated ETFs